BMS is the 12th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies; Permits Designation of One Contract Pharmacy for Three Cancer Drugs

By email dated January 14, 2022, Bristol Myers Squibb (BMS) announced that, effective March 1, 2022, it will implement a new 340B contract pharmacy policy impacting two drug categories: non-immunomodulatory…